O	0	14	Glucocorticoid	Glucocorticoid	NN	B-NP
O	15	23	receptor	receptor	NN	I-NP
O	23	24	-	-	HYPH	B-NP
O	24	31	induced	induce	VBN	I-NP
O	32	36	MAPK	MAPK	NN	I-NP
O	37	48	phosphatase	phosphatase	NN	I-NP
O	48	49	-	-	HYPH	B-NP
O	49	50	1	1	CD	I-NP
O	51	52	(	(	(	O
O	52	55	MPK	MPK	NN	O
O	55	56	-	-	HYPH	O
O	56	57	1	1	CD	O
O	57	58	)	)	)	O
O	59	69	expression	expression	NN	B-NP
O	70	78	inhibits	inhibit	VBZ	B-VP
O	79	89	paclitaxel	paclitaxel	NN	B-NP
O	89	90	-	-	HYPH	O
O	90	100	associated	associate	VBN	B-NP
O	101	105	MAPK	MAPK	NN	I-NP
O	106	116	activation	activation	NN	I-NP
O	117	120	and	and	CC	O
O	121	132	contributes	contribute	VBZ	B-VP
O	133	135	to	to	TO	B-PP
B-Cell	136	142	breast	breast	NN	B-NP
I-Cell	143	149	cancer	cancer	NN	I-NP
I-Cell	150	154	cell	cell	NN	I-NP
O	155	163	survival	survival	NN	I-NP
O	163	164	.	.	.	O

O	166	180	Glucocorticoid	Glucocorticoid	NN	B-NP
O	181	189	receptor	receptor	NN	I-NP
O	190	191	(	(	(	O
O	191	193	GR	GR	NN	B-NP
O	193	194	)	)	)	O
O	195	205	activation	activation	NN	B-NP
O	206	209	has	have	VBZ	B-VP
O	210	218	recently	recently	RB	I-VP
O	219	223	been	be	VBN	I-VP
O	224	229	shown	show	VBN	I-VP
O	230	232	to	to	TO	I-VP
O	233	240	inhibit	inhibit	VB	I-VP
O	241	250	apoptosis	apoptosis	NN	B-NP
O	251	253	in	in	IN	B-PP
B-Cell	254	260	breast	breast	NN	B-NP
I-Cell	261	271	epithelial	epithelial	JJ	I-NP
I-Cell	272	277	cells	cell	NNS	I-NP
O	277	278	.	.	.	O

O	279	281	We	We	PRP	B-NP
O	282	286	have	have	VBP	B-VP
O	287	297	previously	previously	RB	I-VP
O	298	307	described	describe	VBN	I-VP
O	308	309	a	a	DT	B-NP
O	310	315	group	group	NN	I-NP
O	316	318	of	of	IN	B-PP
O	319	324	genes	gene	NNS	B-NP
O	325	329	that	that	WDT	B-NP
O	330	332	is	be	VBZ	B-VP
O	333	340	rapidly	rapidly	RB	B-ADVP
O	341	343	up	up	RB	B-ADVP
O	343	344	-	-	HYPH	B-NP
O	344	353	regulated	regulate	VBN	B-VP
O	354	356	in	in	IN	B-PP
O	357	362	these	these	DT	B-NP
B-Cell	363	368	cells	cell	NNS	I-NP
O	369	378	following	follow	VBG	B-PP
O	379	392	dexamethasone	dexamethasone	NN	B-NP
O	393	394	(	(	(	O
O	394	397	Dex	Dex	NN	B-NP
O	397	398	)	)	)	O
O	399	408	treatment	treatment	NN	B-NP
O	408	409	.	.	.	O

O	410	412	In	In	IN	B-PP
O	413	415	an	an	DT	B-NP
O	416	422	effort	effort	NN	I-NP
O	423	425	to	to	TO	B-VP
O	426	433	dissect	dissect	VB	I-VP
O	434	437	the	the	DT	B-NP
O	438	448	mechanisms	mechanism	NNS	I-NP
O	449	451	of	of	IN	B-PP
O	452	454	GR	GR	NN	B-NP
O	454	455	-	-	HYPH	B-NP
O	455	463	mediated	mediate	VBN	I-NP
B-Cell	464	470	breast	breast	NN	I-NP
I-Cell	471	481	epithelial	epithelial	JJ	I-NP
I-Cell	482	486	cell	cell	NN	I-NP
O	487	495	survival	survival	NN	I-NP
O	495	496	,	,	,	O
O	497	499	we	we	PRP	B-NP
O	500	503	now	now	RB	B-ADVP
O	504	511	examine	examine	VBP	B-VP
O	512	515	the	the	DT	B-NP
O	516	525	molecular	molecular	JJ	I-NP
O	526	532	events	event	NNS	I-NP
O	533	543	downstream	downstream	JJ	B-ADJP
O	544	546	of	of	IN	B-PP
O	547	549	GR	GR	NN	B-NP
O	550	560	activation	activation	NN	I-NP
O	560	561	.	.	.	O

O	562	566	Here	Here	RB	B-ADVP
O	567	569	we	we	PRP	B-NP
O	570	574	show	show	VBP	B-VP
O	575	579	that	that	IN	B-SBAR
O	580	582	GR	GR	NN	B-NP
O	583	593	activation	activation	NN	I-NP
O	594	599	leads	lead	VBZ	B-VP
O	600	602	to	to	TO	B-PP
O	603	607	both	both	CC	O
O	608	611	the	the	DT	B-NP
O	612	617	rapid	rapid	JJ	I-NP
O	618	627	induction	induction	NN	I-NP
O	628	630	of	of	IN	B-PP
O	631	635	MAPK	MAPK	NN	B-NP
O	636	647	phosphatase	phosphatase	NN	I-NP
O	647	648	-	-	HYPH	B-NP
O	648	649	1	1	CD	I-NP
O	650	651	(	(	(	O
O	651	654	MKP	MKP	NN	O
O	654	655	-	-	HYPH	O
O	655	656	1	1	CD	O
O	656	657	)	)	)	O
O	658	662	mRNA	mRNA	NN	B-NP
O	663	666	and	and	CC	O
O	667	670	its	its	PRP$	B-NP
O	671	680	sustained	sustained	JJ	I-NP
O	681	691	expression	expression	NN	I-NP
O	691	692	.	.	.	O

O	693	702	Induction	Induction	NN	B-NP
O	703	705	of	of	IN	B-PP
O	706	709	the	the	DT	B-NP
O	710	713	MKP	MKP	NN	I-NP
O	713	714	-	-	HYPH	B-NP
O	714	715	1	1	CD	I-NP
O	716	723	protein	protein	NN	I-NP
O	724	726	in	in	IN	B-PP
O	727	730	the	the	DT	B-NP
B-Cell	731	737	MCF10A	MCF10A	NN	I-NP
I-Cell	737	738	-	-	HYPH	B-NP
I-Cell	738	741	Myc	Myc	NN	I-NP
O	742	745	and	and	CC	I-NP
B-Cell	746	749	MDA	MDA	NN	I-NP
I-Cell	749	750	-	-	HYPH	B-NP
I-Cell	750	752	MB	MB	NN	I-NP
I-Cell	752	753	-	-	HYPH	I-NP
I-Cell	753	756	231	231	CD	I-NP
I-Cell	757	763	breast	breast	NN	I-NP
I-Cell	764	774	epithelial	epithelial	JJ	I-NP
I-Cell	775	779	cell	cell	NN	I-NP
I-Cell	780	785	lines	line	NNS	I-NP
O	786	789	was	be	VBD	B-VP
O	790	794	also	also	RB	I-VP
O	795	799	seen	see	VBN	I-VP
O	799	800	.	.	.	O

O	801	811	Paclitaxel	Paclitaxel	NN	B-NP
O	812	821	treatment	treatment	NN	I-NP
O	822	830	resulted	result	VBD	B-VP
O	831	833	in	in	IN	B-PP
O	834	838	MAPK	MAPK	NN	B-NP
O	839	849	activation	activation	NN	B-NP
O	850	853	and	and	CC	O
O	854	863	apoptosis	apoptosis	NN	B-NP
O	864	866	of	of	IN	B-PP
B-Cell	867	870	MDA	MDA	NN	B-NP
I-Cell	870	871	-	-	HYPH	B-NP
I-Cell	871	873	MB	MB	NN	I-NP
I-Cell	873	874	-	-	HYPH	I-NP
I-Cell	874	877	231	231	CD	I-NP
I-Cell	878	884	breast	breast	NN	I-NP
I-Cell	885	891	cancer	cancer	NN	I-NP
I-Cell	892	897	cells	cell	NNS	I-NP
O	897	898	,	,	,	O
O	899	902	and	and	CC	O
O	903	907	both	both	DT	B-NP
O	908	917	processes	process	NNS	I-NP
O	918	922	were	be	VBD	B-VP
O	923	932	inhibited	inhibit	VBN	I-VP
O	933	935	by	by	IN	B-PP
O	936	939	Dex	Dex	NN	B-NP
O	940	952	pretreatment	pretreatment	NN	I-NP
O	952	953	.	.	.	O

O	954	965	Furthermore	Furthermore	RB	B-ADVP
O	965	966	,	,	,	O
O	967	976	induction	induction	NN	B-NP
O	977	979	of	of	IN	B-PP
O	980	983	MKP	MKP	NN	B-NP
O	983	984	-	-	HYPH	B-NP
O	984	985	1	1	CD	I-NP
O	986	996	correlated	correlate	VBD	B-VP
O	997	1001	with	with	IN	B-PP
O	1002	1005	the	the	DT	B-NP
O	1006	1016	inhibition	inhibition	NN	I-NP
O	1017	1019	of	of	IN	B-PP
O	1020	1033	extracellular	extracellular	JJ	B-NP
O	1034	1040	signal	signal	NN	I-NP
O	1040	1041	-	-	HYPH	B-NP
O	1041	1050	regulated	regulate	VBN	I-NP
O	1051	1057	kinase	kinase	NN	I-NP
O	1058	1059	(	(	(	O
O	1059	1063	ERK1	ERK1	NN	B-NP
O	1063	1064	/	/	SYM	O
O	1064	1065	2	2	CD	B-NP
O	1065	1066	)	)	)	O
O	1067	1070	and	and	CC	O
O	1071	1072	c	c	NN	O
O	1072	1073	-	-	HYPH	O
O	1073	1076	Jun	Jun	NN	B-NP
O	1077	1078	N	N	NN	I-NP
O	1078	1079	-	-	HYPH	B-NP
O	1079	1087	terminal	terminal	JJ	I-NP
O	1088	1094	kinase	kinase	NN	I-NP
O	1095	1096	(	(	(	O
O	1096	1099	JNK	JNK	NN	B-NP
O	1099	1100	)	)	)	O
O	1101	1109	activity	activity	NN	B-NP
O	1109	1110	,	,	,	O
O	1111	1118	whereas	whereas	IN	O
O	1119	1122	p38	p38	NN	B-NP
O	1123	1131	activity	activity	NN	I-NP
O	1132	1135	was	be	VBD	B-VP
O	1136	1145	minimally	minimally	RB	I-VP
O	1146	1154	affected	affect	VBN	I-VP
O	1154	1155	.	.	.	O

O	1156	1164	Blocking	Block	VBG	B-NP
O	1165	1168	Dex	Dex	NN	I-NP
O	1168	1169	-	-	HYPH	O
O	1169	1176	induced	induce	VBN	B-NP
O	1177	1180	MKP	MKP	NN	I-NP
O	1180	1181	-	-	HYPH	B-NP
O	1181	1182	1	1	CD	I-NP
O	1183	1192	induction	induction	NN	I-NP
O	1193	1198	using	use	VBG	B-VP
O	1199	1204	small	small	JJ	B-NP
O	1205	1216	interfering	interfere	VBG	I-NP
O	1217	1220	RNA	RNA	NN	I-NP
O	1221	1230	increased	increase	VBD	B-VP
O	1231	1235	ERK1	ERK1	NN	B-NP
O	1235	1236	/	/	SYM	O
O	1236	1237	2	2	CD	B-NP
O	1238	1241	and	and	CC	O
O	1242	1245	JNK	JNK	NN	B-NP
O	1246	1261	phosphorylation	phosphorylation	NN	I-NP
O	1262	1265	and	and	CC	O
O	1266	1275	decreased	decrease	VBD	B-VP
B-Cell	1276	1280	cell	cell	NN	B-NP
O	1281	1289	survival	survival	NN	I-NP
O	1289	1290	.	.	.	O

O	1291	1295	ERK1	ERK1	NN	B-NP
O	1295	1296	/	/	SYM	I-NP
O	1296	1297	2	2	CD	I-NP
O	1298	1301	and	and	CC	I-NP
O	1302	1305	JNK	JNK	NN	I-NP
O	1306	1318	inactivation	inactivation	NN	I-NP
O	1319	1322	was	be	VBD	B-VP
O	1323	1333	associated	associate	VBN	I-VP
O	1334	1338	with	with	IN	B-PP
O	1339	1342	Ets	Ets	NN	B-NP
O	1342	1343	-	-	HYPH	B-NP
O	1343	1347	like	like	JJ	I-NP
O	1348	1361	transcription	transcription	NN	I-NP
O	1362	1368	factor	factor	NN	I-NP
O	1368	1369	-	-	HYPH	B-NP
O	1369	1370	1	1	CD	I-NP
O	1371	1372	(	(	(	O
O	1372	1375	ELK	ELK	NN	O
O	1375	1376	-	-	HYPH	O
O	1376	1377	1	1	CD	O
O	1377	1378	)	)	)	O
O	1379	1396	dephosphorylation	dephosphorylation	NN	B-NP
O	1396	1397	.	.	.	O

O	1398	1400	To	To	TO	B-VP
O	1401	1408	explore	explore	VB	I-VP
O	1409	1412	the	the	DT	B-NP
O	1413	1417	gene	gene	NN	I-NP
O	1418	1428	expression	expression	NN	I-NP
O	1429	1436	changes	change	NNS	I-NP
O	1437	1441	that	that	WDT	B-NP
O	1442	1447	occur	occur	VBP	B-VP
O	1448	1458	downstream	downstream	RB	B-ADVP
O	1459	1461	of	of	IN	B-PP
O	1462	1465	ELK	ELK	NN	B-NP
O	1465	1466	-	-	HYPH	B-NP
O	1466	1467	1	1	CD	I-NP
O	1468	1485	dephosphorylation	dephosphorylation	NN	I-NP
O	1485	1486	,	,	,	O
O	1487	1489	we	we	PRP	B-NP
O	1490	1494	used	use	VBD	B-VP
O	1495	1496	a	a	DT	B-NP
O	1497	1508	combination	combination	NN	I-NP
O	1509	1511	of	of	IN	B-PP
O	1512	1520	temporal	temporal	JJ	B-NP
O	1521	1525	gene	gene	NN	I-NP
O	1526	1536	expression	expression	NN	I-NP
O	1537	1541	data	datum	NNS	I-NP
O	1542	1545	and	and	CC	O
O	1546	1554	promoter	promoter	NN	B-NP
O	1555	1562	element	element	NN	I-NP
O	1563	1571	analyses	analysis	NNS	I-NP
O	1571	1572	.	.	.	O

O	1573	1577	This	This	DT	B-NP
O	1578	1586	approach	approach	NN	I-NP
O	1587	1595	revealed	reveal	VBD	B-VP
O	1596	1597	a	a	DT	B-NP
O	1598	1608	previously	previously	RB	I-NP
O	1609	1621	unrecognized	unrecognized	JJ	I-NP
O	1622	1637	transcriptional	transcriptional	JJ	I-NP
O	1638	1644	target	target	NN	I-NP
O	1645	1647	of	of	IN	B-PP
O	1648	1651	ELK	ELK	NN	B-NP
O	1651	1652	-	-	HYPH	B-NP
O	1652	1653	1	1	CD	I-NP
O	1653	1654	,	,	,	O
O	1655	1658	the	the	DT	B-NP
O	1659	1664	human	human	JJ	I-NP
O	1665	1671	tissue	tissue	NN	I-NP
O	1672	1683	plasminogen	plasminogen	NN	I-NP
O	1684	1693	activator	activator	NN	I-NP
O	1694	1695	(	(	(	O
O	1695	1698	tPA	tPA	NN	B-NP
O	1698	1699	)	)	)	O
O	1699	1700	.	.	.	O

O	1701	1703	We	We	PRP	B-NP
O	1704	1712	verified	verify	VBD	B-VP
O	1713	1716	the	the	DT	B-NP
O	1717	1726	predicted	predict	VBN	I-NP
O	1727	1730	ELK	ELK	NN	I-NP
O	1730	1731	-	-	HYPH	B-NP
O	1731	1732	1	1	CD	I-NP
O	1732	1733	-	-	HYPH	B-NP
O	1733	1734	-	-	HYPH	I-NP
O	1734	1735	>	>	SYM	I-NP
O	1736	1739	tPA	tPA	NN	I-NP
O	1740	1755	transcriptional	transcriptional	JJ	I-NP
O	1756	1766	regulatory	regulatory	JJ	I-NP
O	1767	1779	relationship	relationship	NN	I-NP
O	1780	1785	using	use	VBG	B-VP
O	1786	1787	a	a	DT	B-NP
O	1788	1798	luciferase	luciferase	NN	I-NP
O	1799	1807	reporter	reporter	NN	I-NP
O	1808	1813	assay	assay	NN	I-NP
O	1813	1814	.	.	.	O

O	1815	1817	We	We	PRP	B-NP
O	1818	1826	conclude	conclude	VBP	B-VP
O	1827	1831	that	that	IN	B-SBAR
O	1832	1834	GR	GR	NN	B-NP
O	1834	1835	-	-	HYPH	B-NP
O	1835	1843	mediated	mediate	VBN	I-NP
O	1844	1848	MAPK	MAPK	NN	I-NP
O	1849	1861	inactivation	inactivation	NN	I-NP
O	1862	1873	contributes	contribute	VBZ	B-VP
O	1874	1876	to	to	TO	B-PP
B-Cell	1877	1881	cell	cell	NN	B-NP
O	1882	1890	survival	survival	NN	I-NP
O	1891	1894	and	and	CC	O
O	1895	1899	that	that	IN	B-SBAR
O	1900	1903	the	the	DT	B-NP
O	1904	1913	potential	potential	JJ	I-NP
O	1914	1929	transcriptional	transcriptional	JJ	I-NP
O	1930	1937	targets	target	NNS	I-NP
O	1938	1940	of	of	IN	B-PP
O	1941	1945	this	this	DT	B-NP
O	1946	1956	inhibition	inhibition	NN	I-NP
O	1957	1960	can	can	MD	B-VP
O	1961	1963	be	be	VB	I-VP
O	1964	1974	identified	identify	VBN	I-VP
O	1975	1979	from	from	IN	B-PP
O	1980	1985	large	large	JJ	B-NP
O	1986	1991	scale	scale	NN	I-NP
O	1992	1996	gene	gene	NN	I-NP
O	1997	2002	array	array	NN	I-NP
O	2003	2011	analysis	analysis	NN	I-NP
O	2011	2012	.	.	.	O

